# A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

> **NCT05234437** · PHASE2 · TERMINATED · sponsor: **QBiotics Group Limited** · enrollment: 1 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** tigilanol tiglate

## Key facts

- **NCT ID:** NCT05234437
- **Lead sponsor:** QBiotics Group Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-09
- **Primary completion:** 2022-07-18
- **Final completion:** 2022-07-18
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Insufficient Patient Recruitment Rates
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05234437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05234437, "A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05234437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*